Harry L.A. Janssen's research while affiliated with Michael Garron Hospital and other places

... 142 Several scores, including the LiverRisk, SAFE and MAF-5 score are currently being developed for the population-based setting. [143][144][145] Future studies will need to address how these scores perform regarding accuracy, in sequential testing and regarding cost-effectiveness. ...

Reference:

EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

... Hence, per-protocol NA cessation after HBsAg seroclearance is the common practice in these programmes. HBsAg seroreversion may occur in some patients if HBsAg seroclearance resulted from the inhibition of HBsAg expression, namely small interfering RNA (siRNA), or antisense oligonucleotides (ASO) [44] (Table 1). Long-term follow-up data from these programmes would be valuable to ascertain the minimal risk of disease progression in patients who achieved functional cure with these novel HBV therapeutics. ...

Reference:

Hepatocellular carcinoma surveillance after HBsAg seroclearance

... Further, we tried to analyze the role of immunemediated liver damage [18] on the progress of ADV infection. Different cytokines and immune cells were investigated. ...

Reference:

Liver injury and prolonged hospitalization as indicators of severity in patients with adenovirus infections

... In HBeAg-negative patients receiving long-term NAs, the addition of PEG-IFN to long-term NA treatment was associated with a substantial HBsAg decline and 10% HBsAg clearance (10). Low baseline HBsAg levels and early ontreatment HBsAg decline were predictive of subsequent HBsAg clearance (10). ...

Reference:

A Case of Chronic Hepatitis B in which HBs Antigen Seroclearance was Induced by Pegpegylated-interferonα-2a after Hepatocellular Carcinoma Treatment with Nucleos(t)ide Analogues: A Five-year Follow-up

... It is particularly noteworthy that the effectiveness of the PAGE-B score in predicting HCC has not been thoroughly evaluated in patients of African origin, a population in which CHB is a significant cause of morbidity and mortality. A recent study by Patmore et al. [43] highlighted the association between HCC incidence and varying levels of the PAGE-B score in hepatitis B patients of African descent. Specifically, the risk of HCC was negligible among individuals without advanced fibrosis and a low baseline (m)PAGE-B score. ...

Reference:

Evaluation of PAGE-B Score for Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients: Reliability, Validity, and Responsiveness

... To the editor, When Jeng et al [1] reported that stopping antivirals in patients with cirrhosis and chronic hepatitis B had better outcomes than continuing therapy, debate followed. [2,3] Similarly, we are concerned with several issues that affect the interpretation of this study. ...

Reference:

Letter to the Editor: Halting antiviral therapy in patients with cirrhosis and chronic hepatitis B: A dangerous game?

... Five-year (week 240) results from the international cohort confirm the favorable long-term safety of TAF. 17 Here we report the 5-year (week 240) efficacy and safety results from the China 108 and 110 cohorts. We highlight findings from both studies, including the long-term efficacy and safety of continuous TAF treatment as well as the impact of switching to TAF after receiving 3 years of TDF treatment. ...

Reference:

Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients

... Indeed, it is important to note that recent trials of siRNAs have all benefitted from the addition of immune modulators, most commonly peg-IFN-α. Even bepirovirsen, a leading antisense RNA candidate for HBV, which did not explicitly benefit from additional peg-IFN-α, has been found to have intrinsic immunostimulatory activity [125,126]. Systemic peg-IFN-α clearly upregulates several of the ISGs that are also HBV restriction factors, described above. It is notable that peg-IFN-α has a higher rate of HBsAg clearance, i.e., a functional cure, compared to NUCs, the mainstay of CHB treatment, underscoring the potency of the suite of restriction factors described here. ...

Reference:

Intracellular Host Restriction of Hepatitis B Virus Replication

... Most patients have undetectable viremia and normal liver biochemistry after HBsAg seroclearance, and less than 5% of patients have HBsAg reversion after seroclearance [2]. This translates into a much-reduced risk of HCC and cirrhotic complications [3]. As clearance of intrahepatic covalently closed circular DNA (cccDNA) and integrated HBV DNA is unlikely to be achieved in the foreseeable future using current technologies, sustained HBsAg seroclearance with serum HBV DNA less than the lower limit of quantitation is generally accepted as the functional cure of CHB [4]. ...

Reference:

Hepatocellular carcinoma surveillance after HBsAg seroclearance

... Our study utilized liver fine-needle aspirates for single-cell sequencing of B cells, while others such as Zhang et al. [9] and Bai et al. [10] performed single-cell sequencing on core liver biopsies after enzymatic digestion of liver tissues and sorting of CD45-positive leukocytes. As reported previously, the use of liver fine-needle aspirates avoids the time and sample manipulation involved with digestion and cell sorting and allows the collection of liver material from patients on a voluntary basis even without a medical indication to do so [11]. However, despite efforts to validate our findings using publically available datasets, the methodological differences prevented reliable comparisons between datasets. ...

Reference:

Intrahepatic plasma cells, but not atypical memory B cells, associate with clinical phases of chronic hepatitis B